We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04527250
Previous Study | Return to List | Next Study

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04527250
Recruitment Status : Completed
First Posted : August 26, 2020
Last Update Posted : August 20, 2021
Sponsor:
Collaborator:
Hunan Provincial People's Hospital
Information provided by (Responsible Party):
Ascletis Pharmaceuticals Co., Ltd.

Tracking Information
First Submitted Date  ICMJE August 23, 2020
First Posted Date  ICMJE August 26, 2020
Last Update Posted Date August 20, 2021
Actual Study Start Date  ICMJE September 16, 2020
Actual Primary Completion Date December 18, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 23, 2020)
Evaluation of the safety and tolerability of ASC41 in healthy volunteers [ Time Frame: Up to 32 days ]
Evaluation of the safety and tolerability of ASC41 in healthy volunteers
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 23, 2020)
  • Cmax of ASC41 [ Time Frame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days. ]
    Evaluate the Peak Plasma Concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.
  • Tmax of ASC41 [ Time Frame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days. ]
    Evaluate the Time to reach the maximum plasma concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.
  • AUC of ASC41 [ Time Frame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days. ]
    Evaluate the Area under the plasma concentration versus time curve after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.
  • t1/2 of ASC41 [ Time Frame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days. ]
    Evaluate the Terminal-Phase Half-Life after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers volunteers.
  • CL/F of ASC41 [ Time Frame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days. ]
    Evaluate the Apparent Systemic Clearance after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.
  • Vd/F of ASC41 [ Time Frame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days. ]
    Evaluate the Apparent Volume of Distribution after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of the Relative Bioavailability of ASC41 in Healthy Subjects
Official Title  ICMJE Comparison of the Pharmacokinetic Parameters of ASC41, a Randomized, Double-blind, Placebo-controlled in Healthy Subjects After Single and Multiple Doses
Brief Summary The objective of this study is to compare the pharmacokinetic parameters of ASC41 in healthy subjects after single and multiple oral dosing.
Detailed Description The purpose of this study was to evaluate the tolerability, safety pharmacokinetics and pharmacodynamic (biomarkers) of ASC41 tables in a randomized, double-blind, placebo-controlled single- and multiple-dose phase I clinical trial in healthy subjects the study. The effects of ASC41 on LDL-C and other lipid parameters (TG, TC, HDL-C, etc.) will be observed after repeated administration of ASC41 in healthy subjects.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: ASC41
    ASC41,1mg/table;5mg/table
  • Drug: ASC41 placebo
    ASC41 placebo,1mg/table;5mg/table
Study Arms  ICMJE
  • Experimental: Experimental:1mg
    ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
    Intervention: Drug: ASC41
  • Experimental: Experimental:2mg
    ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
    Intervention: Drug: ASC41
  • Experimental: Experimental:5mg
    ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
    Intervention: Drug: ASC41
  • Experimental: Experimental:10mg
    ASC41 two tablets (10mg) single oral dose at Day 1.
    Intervention: Drug: ASC41
  • Experimental: Experimental:20mg
    ASC41 four tablets (20mg) single oral dose at Day 1.
    Intervention: Drug: ASC41
  • Placebo Comparator: Placebo:1mg
    ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
    Intervention: Drug: ASC41 placebo
  • Placebo Comparator: Placebo:2mg
    ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
    Intervention: Drug: ASC41 placebo
  • Placebo Comparator: Placebo:5mg
    ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
    Intervention: Drug: ASC41 placebo
  • Placebo Comparator: Placebo:10mg
    ASC41 placebo two tablets (10mg) single oral dose at Day 1.
    Intervention: Drug: ASC41 placebo
  • Placebo Comparator: Placebo:20mg
    ASC41 placebo four tablets (20mg) single oral dose at Day 1.
    Intervention: Drug: ASC41 placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 19, 2021)
60
Original Estimated Enrollment  ICMJE
 (submitted: August 23, 2020)
65
Actual Study Completion Date  ICMJE December 30, 2020
Actual Primary Completion Date December 18, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 1. Age 18-45 (including boundary value). 2. Male weight ≥ 50kg, female weight ≥ 45kg;BMI ranges from 19 to 30kg/m2 (boundary value included).

    3. She is of childbearing potential and is non-pregnant and willing to use adequate contraception from screening (within 30days from the first administration)until one month after the End of Study visit.

    4. The pregnancy test of female subjects during the screening period is negative.

    5. During the screening period, fasting low-density lipoprotein cholesterol (110mg/dl < fasting (LDL-C) < 190mg/ dL.

    6. Those who voluntarily sign the informed consent.

Exclusion Criteria:

  • 1. Patients with a history of thyroid disease or intolerance to beta blockers or abnormal thyroid function indicators during screening; 2. Previous history of fainting, fainting needle or fainting blood for unknown reasons.

    3. Previous liver disease, or ALT, ASL and direct bilirubin in screening period exceed the normal range.

    4. Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV Ab), HIV antibody (HIV Ab) and syphilis antibody are tested positive.

    5. People who have taken special diet (including carambola, dragon fruit, mango, grapefruit, orange, etc.) or drunk alcohol, or had strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion within 2 weeks before taking the study drug.

    6. Heavy smokers (14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine;Smoking daily ≥ 5 sticks) and no smoking or alcohol prohibition during the study period.

    7. Ingesting chocolate, any food or drink containing caffeine or xanthine in the 24 hours prior to taking the study drug.

    8. Patients who had donated blood or lost blood of more than 400ml within 3 months before taking the study drug.

    9. Those who have participated in other clinical trials and received study drug treatment within 3 months before taking study drug.

    10. In addition to the above, the researchers judge that the participants are not suitable to participate in this clinical trial.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04527250
Other Study ID Numbers  ICMJE ASC-ASC41-I-CTP-02
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party Ascletis Pharmaceuticals Co., Ltd.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Ascletis Pharmaceuticals Co., Ltd.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Hunan Provincial People's Hospital
Investigators  ICMJE Not Provided
PRS Account Ascletis Pharmaceuticals Co., Ltd.
Verification Date August 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP